JOHNSON v. SMITHKLINE BEECHAM CORPORATION

CourtDistrict Court, E.D. Pennsylvania
DecidedAugust 5, 2025
Docket2:11-cv-05782
StatusUnknown

This text of JOHNSON v. SMITHKLINE BEECHAM CORPORATION (JOHNSON v. SMITHKLINE BEECHAM CORPORATION) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
JOHNSON v. SMITHKLINE BEECHAM CORPORATION, (E.D. Pa. 2025).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA GLENDA JOHNSON, et al., : : v. : Civ. No. 11-5782 : and all related cases SMITHKLINE BEECHAM : CORPORATION, et al. :

Diamond, J. August 5, 2025 MEMORANDUM OPINION Beginning in 2011, fifty-two Plaintiffs brought products liability actions against the manufacturers of the morning sickness drug thalidomide, which Plaintiffs alleged their expectant mothers had ingested in the early 1960s, causing Plaintiffs to sustain horrible birth injuries. In 2014, after Plaintiffs repeatedly obstructed Defendants’ efforts to discover whether these actions were time-barred, I appointed William T. Hangley to serve as Special Discovery Master. Having conducted a painstaking inquiry against often fierce and unprincipled resistance, Mr. Hangley has issued a Report and Recommendation in which he finds that Plaintiffs’ counsel—the law firm of Hagens Berman Sobol and Shapiro, its Managing Partner Steve Berman, and former partner Tyler Weaver—had: conducted grossly inadequate presuit investigations; obstructed discovery; recklessly (or, perhaps, intentionally) made false and baseless allegations intended to toll the limitations clock; doctored evidence; and—when their misconduct came to light—sought to abandon Plaintiffs and evade Defendants’ sanctions requests. I will here address the Objections to the R&R that the Firm, Mr. Berman, and Mr. Weaver have raised. Having reviewed all Mr. Hangley’s findings and conclusions de novo, I will adopt Mr. Hangley’s Recommendations respecting Hagens Berman’s Motions to Withdraw from representing a number of Plaintiffs. I will not adopt the Special Master’s Recommendation to deny without prejudice Hagens Berman’s Motion to Withdraw from the representation of a Plaintiff who has abandoned his claims. I will not adopt Mr. Hangley’s Recommendation to impose sanctions on Hagens Berman, Mr. Berman, and Mr. Weaver. Rather, as I stated in my prior Order, I will treat the R&R as notice to the Firm and Messrs. Berman and Weaver. (Doc. No. 768.) I will require: Hagens Berman to

show cause why sanctions should not be imposed pursuant to Fed. R. Civ. P. 26(g), and 37; Hagens Berman and Mr. Berman to show cause why sanctions should not be imposed under Pa. R. Civ. P. 1023.1(d), Fed. R. Civ. P. 11(c), and 28 U.S.C. § 1927; and Hagens Berman, Mr. Berman, and Mr. Weaver to show cause why sanctions should not be imposed under the inherent power of the Court, Chambers v. NASCO, Inc., 501 U.S. 32, 45-46 (1991). The Parties have not objected to the great majority of Mr. Hangley’s factual findings, which, in any event, I have reviewed de novo and adopt. I will thus rely on those undisputed facts throughout this Memorandum. I. BACKGROUND

From 2011 to 2014, Hagens Berman prosecuted eleven products liability actions on behalf of fifty-two individual Plaintiffs against pharmaceutical companies GlaxoSmithKline, Grünenthal, Sanofi, and Avantor. Each Plaintiff alleged that in the early 1960s, thalidomide—a maternity drug manufactured by the Defendants or their legal predecessors—had caused severe birth defects. Each Complaint save one was initially filed in state court and removed to this Court. See Johnson v. SmithKline Beecham Corp., 724 F.3d 337, 360 (3d Cir. 2013). The Parties did not dispute that there was complete diversity between Plaintiffs and all Defendants except GSK. The Third Circuit accepted the question I had certified for interlocutory review: whether there was diversity jurisdiction over GSK. Id. at 340-41. Ruling that there was diversity jurisdiction, the Court remanded. Id. at 360. Chief Judge Tucker then consolidated all eleven Hagens Berman actions before me. (Doc. Nos. 81, 88, 94, 181.) Defendants vigorously argued that I should dismiss all claims as barred by Pennsylvania’s two-year limitations clock governing tort actions. See 42 Pa. Cons. Stat. § 5524. Plaintiffs variously pled: that Defendants’ fraudulent concealment had tolled the running of the limitations

clock; or, due to advances in medical science, Plaintiffs could not reasonably have discovered until very recently that thalidomide had caused their birth injuries. (Doc. No. 76.) I was obligated at the Rule 12(b)(6) stage to accept these allegations. Accordingly, I denied Defendants’ Motions to Dismiss. (Doc. No. 92); see also Van Buskirk v. Carey Canadian Mines, Ltd., 760 F.2d 481, 498 (3d Cir. 1985) (“Since the applicability of the statute of limitations usually involves questions of fact for the jury, defendants bear a heavy burden in seeking to establish as a matter of law that the challenged claims are barred.”). Given that Plaintiffs had sustained their injuries some 50 years before they filed suit, and given Plaintiffs’ tolling allegations, Defendants sought to learn in discovery if the suits were time-

barred: i.e., when each Plaintiff knew or should have known that thalidomide may have caused his or her injuries. (See Doc. No. 95.) As I have previously described in detail, Hagens Berman repeatedly failed to provide this potentially dispositive information. (See, e.g., Doc. Nos. 147, 154, 166, 206, 222.) On March 26, 2014, GSK wrote to Hagens Berman that it was “obvious that in all or most of [the cases] no reasonable pre-suit investigation was conducted,” asked the Firm “to undertake a careful review of the claims made in all these cases,” and offered that “in any such case dismissed by April 11,” GSK would not seek sanctions. (See Doc. No. 310-5 at 2 of 27.) No cases were dismissed by that deadline. (See Docket.) On June 12, 2014, Defendants asked me to dismiss all eleven Complaints with prejudice on discovery abuse grounds. (Doc. No. 232.) Although I denied the request, I noted that I was “greatly concerned that Plaintiffs ha[d] not honored their discovery obligations with respect to [the] critical issue” of Plaintiffs’ knowledge of their birth injuries. (Doc. No. 239 at 3.) Accordingly, on June 27, 2014, with the consent of all Parties, I appointed Mr. Hangley as Special Discovery Master to “investigat[e] and supervis[e] all discovery respecting the Thalidomide

discovery issue,” “[m]onitor[] and report[] on Plaintiffs’ compliance with their discovery and disclosure obligations respecting the Thalidomide discovery issue,” and “ensure Plaintiffs’ compliance with [those] obligations.” (Doc. No. 256 at 1-2); see also Fed. R. Civ. P. 53(b)(1). This Order also included the common provision that the Special Master could “communicate ex parte with the Court . . . for any . . . reason reasonably necessary to the fulfillment of his duties.” (Doc. No. 256 at 3); see also, e.g., Arneault v. O’Toole, No. 11-95, 2016 WL 7029620, at *4 (W.D. Pa. Dec. 2, 2016) (“[T]he Special Master may communicate with the Court ex parte on all matters as to which the Special Master has been empowered to act.”), aff’d, 718 F. App'x 148 (3d Cir. 2017); In re Flint Water Cases, No. 16-10444, 2018 WL 11290659, at *2 (E.D. Mich. July 31,

2018) (“Pursuant to Rule 53(b)(2)(B), the Special Master may communicate ex parte with the Court at any time.”); Moussouris v. Microsoft Corp., No. C15-1483, 2017 WL 1652910, at *1 (W.D. Wash.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Chambers v. Nasco, Inc.
501 U.S. 32 (Supreme Court, 1991)
In Re: Brooks
383 F.3d 1036 (D.C. Circuit, 2004)
Erie Molded Plastics, Inc. v. Nogah, LLC
520 F. App'x 82 (Third Circuit, 2013)
Glenda Johnson v. SmithKline Beecham Corp
724 F.3d 337 (Third Circuit, 2013)
Sands v. McCormick
502 F.3d 263 (Third Circuit, 2007)
United States v. Mercedes-Benz of North America, Inc.
547 F. Supp. 399 (N.D. California, 1982)
Beverly Ohntrup v. Makina Ve Kimya Endustrisi Kur
760 F.3d 290 (Third Circuit, 2014)
Simmerman v. Corino
27 F.3d 58 (Third Circuit, 1994)
Diane S. Blodgett v. John R. Stoebner
343 F. App'x 171 (Eighth Circuit, 2009)
Green v. Nevers
111 F.3d 1295 (Sixth Circuit, 1997)
Donnelly v. Johns-Manville Sales Corp.
677 F.2d 339 (Third Circuit, 1982)

Cite This Page — Counsel Stack

Bluebook (online)
JOHNSON v. SMITHKLINE BEECHAM CORPORATION, Counsel Stack Legal Research, https://law.counselstack.com/opinion/johnson-v-smithkline-beecham-corporation-paed-2025.